Cardiovascular disease in patients with spondyloarthropathies

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Spondyloarthropathies (SpA) present a higher cardiovascular disease (CVD) risk than previously understood.
• Conventional CVD risk factors are prevalent in SpA patients.
• Chronic inflammation in SpA contributes to early atherosclerosis and plaque development.

Purpose of the Study:

• To explore the multifaceted cardiovascular risks associated with spondyloarthropathies.
• To highlight the role of inflammation, genetics, and medications in SpA-related CVD.

Main Methods:

• Review of existing literature on spondyloarthropathies and cardiovascular disease.
• Analysis of risk factors including inflammation, genetic predispositions, and pharmacological treatments.
• Evaluation of the impact of these factors on cardiovascular event occurrence.

Main Results:

• SpA patients exhibit elevated cardiovascular risk beyond known cardiac manifestations.
• Chronic inflammation accelerates atherogenesis in this population.
• Genetic susceptibility genes for SpA may also confer increased CVD risk.
• Certain medications used for SpA treatment can precipitate cardiovascular events.

Conclusions:

• Spondyloarthropathies are linked to significant, multifactorial cardiovascular risks.
• Proactive cardiovascular risk assessment is essential for effective patient management.
• Integrated care addressing both rheumatic and cardiovascular aspects is recommended.